Freudenberg Medical Names Michael McGee as CEO in Leadership Transition

• Michael McGee has been appointed as the new CEO of Freudenberg Medical, effective January 1, 2025.

• Former CEO Dr. Mark Ostwald transitions to another leadership role within the Freudenberg Group.

Freudenberg Medical, a global partner for contract design, development, and manufacturing in the medical device and biopharma industries, has announced a significant leadership change. Effective January 1, 2025, Michael McGee, previously Chief Operating Officer, assumed the position of Chief Executive Officer. He succeeds Dr. Mark Ostwald, who has transitioned to another leadership role within the Freudenberg Group.

Michael McGee joined Freudenberg Medical in 2022 as COO and brings over 30 years of experience in the medical device sector. His appointment underscores the company’s commitment to continuity and its long-term strategic goals. McGee expressed his enthusiasm, saying, “Together, we will build on this strong foundation and drive meaningful advancements in healthcare.”

During his tenure as CEO, Dr. Ostwald led Freudenberg Medical through a period of growth, doubling annual revenue, expanding global manufacturing by a third, and integrating three joint ventures. He shared his confidence in McGee’s leadership, stating, “Michael is passionately committed to our strategy and values… I am convinced that Michael is the right leader to take Freudenberg Medical to the next level of success.”